Carbimazole

Quick links to important sections

Carbimazole

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Carbimazole

What is Carbimazole?

Carbimazole is a pharmaceutical agent categorized as a pro-drug, primarily used in the management of hyperthyroidism. Hyperthyroidism is a clinical condition characterized by an overactive thyroid gland that produces an excess of thyroid hormones, specifically thyroxine (T4) and triiodothyronine (T3).

Mechanism of Action

Upon ingestion, carbimazole is rapidly converted into its active form, methimazole. This active metabolite works by inhibiting the enzyme thyroid peroxidase. This enzyme is essential for the synthesis of thyroid hormones as it facilitates the iodination of tyrosine residues on thyroglobulin and the subsequent coupling of iodotyrosines. By interfering with these biochemical pathways, carbimazole effectively reduces the production of new thyroid hormones.

Clinical Applications

Carbimazole is typically utilized in several clinical contexts related to thyroid dysfunction:

  • Control of Hyperthyroidism: It is used to lower thyroid hormone levels to a state of normal function, known as euthyroidism.
  • Preparation for Surgery: It may be administered to stabilize hormone levels before a thyroidectomy (surgical removal of the thyroid gland).
  • Radioactive Iodine Treatment: It is often used to control symptoms before or after treatment with radioactive iodine.

Pharmacological Profile

Because carbimazole prevents the synthesis of new hormones rather than inhibiting the release of existing stores, there is usually a latent period before clinical symptoms of hyperthyroidism begin to improve. This period corresponds to the time required for the body to deplete the thyroid hormones already circulating in the bloodstream and stored within the thyroid gland.

Regulatory References

  1. Hyperthyroidism: MedlinePlus Medical Encyclopedia

What side effects are possible with Carbimazole?

Possible Side Effects and Safety Information

Carbimazole's official safety profile is structured by classifying potential reactions according to frequency, system involvement, and severity, based on regulatory documentation.

Adverse Reaction Scope

Classification Examples of Officially Documented Reactions
Common Skin rash, pruritus (itching), nausea, headache, arthralgia (joint pain), and mild gastrointestinal disturbance.
Rare/Very Rare Pancytopenia/aplastic anaemia, Stevens-Johnson syndrome, and haemolytic anaemia.
Serious Reactions Agranulocytosis (a potentially fatal blood disorder), severe Hepatic Disorders (including hepatitis and cholestatic jaundice), Acute Pancreatitis, and Vasculitis.

Adverse reactions generally occur in the first eight weeks of treatment. While common reactions are often self-limiting, the development of serious adverse reactions mandates immediate consideration.

Regulatory Safety Considerations

The medicine is contraindicated in several specific situations. These include patients with a history of acute pancreatitis following previous Carbimazole use, pre-existing haematological conditions, or severe hepatic insufficiency.

Official documents also address safety in specific populations. The risk of a fatal outcome from neutrophil dyscrasia (e.g., agranulocytosis) may be greater in older adults. For patients of reproductive potential, effective contraception is advised, as use during pregnancy has been associated with congenital malformations (e.g., choanal atresia). Caution is also advised regarding the potential for cross-allergy with other thioamide derivatives like propylthiouracil.

Overdose and Emergency Response

Carbimazole Overdose and when to seek help

Overdose Manifestations and Severe Outcomes

The official regulatory profile for Carbimazole overdose defines two distinct risk scenarios: acute ingestion and delayed, severe systemic toxicity. Acute ingestion of a single large dose of Carbimazole is officially documented as unlikely to cause symptoms. Consequently, regulatory documents state that no specific treatment is indicated for the immediate acute event.

Overexposure carries a documented risk of severe, delayed, and potentially life-threatening outcomes. These include agranulocytosis, pancytopenia, aplastic anaemia, and severe hepatic damage and acute pancreatitis. These severe conditions may manifest hours or days after the event. The effects of over-suppression can also lead to clinical signs of hypothyroidism. The profile notes that severe adverse reactions in the paediatric population are considered comparable to those in adults.

Required Emergency Actions

If more Carbimazole than prescribed has been taken, contact a doctor or nearest hospital emergency department immediately. Management of toxicity is described as symptomatic and supportive. It is a mandatory requirement to stop the drug and seek medical advice immediately upon the onset of any symptoms suggestive of severe blood disorder (such as an unexplained sore throat, fever, mouth ulcers, or unusual bruising/bleeding) or signs of liver disorder (such as jaundice or severe upper abdominal pain). In such scenarios, immediate blood tests, including white blood cell counts and liver function tests, are required for evaluation.

Therapeutic Uses of Carbimazole

What Carbimazole Treats: Main Uses and Benefits

Carbimazole is a primary treatment used to manage hyperthyroidism (an overactive thyroid gland) and is commonly used across conditions presenting with acute episodes. It helps address the symptoms associated with high thyroid hormone levels. The medication's core benefit is providing support and symptomatic relief.

It is applied in situations involving certain distressing symptoms such as a rapid heart rate and palpitations, internal tremors, and emotional distress like anxiety and irritability. This supportive role is generally applicable when symptoms create noticeable physiological strain and where temporary assistance in symptom stabilization is important. Carbimazole helps address symptom clusters that may become intense or disruptive to functional stability.

Carbimazole is also relevant in clinical settings, often used to achieve a manageable physical state prior to thyroid surgery or before receiving radioactive iodine therapy. This application is relevant in contexts involving heightened systemic burden and may assist with easing the overall symptom burden during treatment phases.


Quick Fact: Relief for symptoms related to systemic imbalance

Eligibility and Restrictions for Use

Carbimazole is contraindicated for several populations, as officially documented in regulatory labeling. The medicine must not be used by patients with a known hypersensitivity to Carbimazole or its excipients, those with serious, pre-existing haematological conditions, or individuals with severe hepatic insufficiency.

Age-Related and Conditional Use

Use is established for adults and for the pediatric population aged 3 to 17 years. Use is not recommended in children below 2 years of age due to insufficient safety data. Older adults (aged 65 or over) may use the medicine, but caution is advised due to a potentially greater risk of a fatal outcome related to blood disorders.

Specific restrictions apply: Carbimazole is contraindicated in patients with a history of acute pancreatitis after its administration. While severe hepatic insufficiency is a contraindication, use is permitted with caution in patients with mild-to-moderate hepatic impairment, but treatment must be immediately stopped if liver function abnormalities are found.

Reproductive Status Restrictions

Women of childbearing potential must use effective contraception during treatment. Carbimazole may only be used during pregnancy after a strict individual assessment of benefits versus risks, only at the lowest effective dose, and when propylthiouracil is not suitable. Because the medicine is secreted into breast milk, breastfeeding should not continue if the patient is undergoing treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Carbimazole and its active metabolite, Methimazole, primarily around two key areas: contraindicated combinations and alterations in the pharmacokinetics of co-administered medicines.

Contraindicated Combinations and Administration Timing

The co-administration of Carbimazole or Methimazole is contraindicated in patients with a history of acute pancreatitis following exposure to the drug. Furthermore, anti-thyroid therapy must be stopped temporarily at the time of Radio-iodine (Sodium Iodide I-131) administration to prevent therapeutic interference.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Official Outcome / Effect
Oral Anticoagulants (e.g., Warfarin) May intensify the anticoagulant effect due to potential inhibition of Vitamin K activity.
Theophylline Clearance may be reduced as the patient becomes euthyroid, leading to potential toxicity if the dosage is not reduced.
Beta-Adrenergic Blockers A reduced dosage may be required upon reaching a euthyroid state due to altered clearance.
Digitalis Glycosides (e.g., Digoxin) Serum levels may be increased when a patient on a stable regimen achieves euthyroidism.
Iodine-Rich Foods Excess iodine intake is documented to attenuate the therapeutic response to Methimazole.

These interactions emphasize the need for close monitoring of plasma levels of co-administered drugs during the patient’s transition from a hyperthyroid to a euthyroid state.

Mechanism of Action

Enzyme Inhibition to Block Thyroid Hormone Synthesis

Carbimazole is a prodrug that converts to the active compound, methimazole (MMI), which acts as an inhibitor of the enzyme Thyroid Peroxidase (TPO) in the thyroid gland. This mechanism directly halts the synthesis of thyroid hormones T3 and T4 by preventing the critical steps of iodine organification and the subsequent coupling of hormone precursors.

Disruption of the Metabolic Cascade

By suppressing the production of T3 and T4, the drug modifies a core endocrine signaling cascade within the body. This disruption leads to a gradual decrease in the circulating levels of these hormones. The resulting physiological effect is an adjustment of the basal metabolic rate, which results in a decrease in the characteristics of the hypermetabolic state and lowered activity in systems like the cardiovascular system.

Modulation of Systemic Physiological Activity

This mechanism primarily targets a peripheral endocrine pathway resulting in reduced concentrations of active hormone affecting end-organ systems. The physiological consequence is a reduction in systemic oxygen consumption and heat production, and a slowing of the heart rate and other overactive physiological responses, resulting in a more regulated concentration of active hormone within the body's major systems.

Dosage and Administration Information

The administration of Carbimazole is defined by a highly structured protocol focusing on the oral route and phased dosing, which is only initiated after hyperthyroidism has been confirmed by laboratory tests.


Administration Scope

Instruction Detail
Route of administration Oral administration via tablet is the standard route.
Dosing schedule (Adults) Initial Phase: Daily dosage is typically 20 mg to 60 mg. Maintenance Phase: The dosage is later reduced to 5 mg to 15 mg per day.
Frequency The initial daily dose is administered in two to three divided doses; the maintenance dose may be taken as a single daily dose.
Timing in relation to meals Can be taken with or without food.

Procedural Principles and Duration

Carbimazole is available in various tablet strengths, including 5 mg, 10 mg, 15 mg, and 20 mg. The tablets must be swallowed whole with water; the score line on some formulations is intended only to facilitate breaking for ease of swallowing and should not be used to divide the dose into unequal parts.

Therapy is structured as a long-term commitment, typically continuing for 12 to 18 months to achieve a stable state, though some courses last for at least six months. Subsequent therapy follows either a Titration Method (dose reduction) or a Blocking-Replacement Regimen (high dose maintained with supplemental L-thyroxine).

For children (aged 3 to 17 years), the usual initial daily dose is 15 mg, and no special dosage regimen is routinely required for older adults.

Recent Clinical Evidence

Carbimazole: Recent Clinical Evidence

This section reviews key research that examined the effects of Carbimazole on symptoms and reported outcomes related to the quality of life in individuals with hyperthyroidism (an overactive thyroid). The research discussed here focuses solely on the clinical trials conducted for the approved indication.


Summary of Mechanism Studied

Research suggests that the drug may act by targeting the synthesis of thyroid hormones (T3 and T4) within the thyroid gland. This interaction was studied for its potential association with the observed clinical effects of normalizing thyroid function.


Key Clinical Trial Findings

Phase 3 Efficacy Data

The initial Phase 3 trials reported statistically relevant differences in the measured primary endpoint (thyroid hormone levels) compared to placebo over the study duration. The study design typically included a placebo-controlled group and measured the primary endpoint over a period designed to assess control of thyroid function. Study data included observations regarding the initial time point at which differences between groups became apparent.

Combination Therapy

Studies evaluated whether combination therapy with Carbimazole and beta-blockers was associated with a difference in short-term symptom management compared to Carbimazole alone. Researchers explored the effect on measures such as heart rate and tremor severity in cohorts with newly diagnosed hyperthyroidism.


Observed Safety Profile

The population in the clinical trials primarily consisted of adults. Reported adverse events included cases of agranulocytosis and liver enzyme elevations, leading to study exclusions for individuals with severe pre-existing liver conditions. The most commonly reported adverse events were consistently documented as mild to moderate in severity, such as headache or skin rash.

Research Status

No major studies have conclusively established the drug's intended effect in pediatric patients. Further research may be undertaken for this age group. The current data collection focused on adults aged 18 to 65. Ongoing Phase 4 studies are continuing to monitor the long-term safety and effects of Carbimazole in a broader patient population.

Key Studies & References

  1. Antithyroid Drugs and Liver Disease: A Systematic Review and Meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Carbimazole (FAQ)

Q: How quickly should I expect to feel better after starting Carbimazole?

A: According to official patient information, some improvement in symptoms is typically felt within the first one to three weeks of starting Carbimazole. However, the full beneficial effects, such as the normalization of your thyroid hormone levels, usually take a longer period, often requiring four to eight weeks.

Q: What should I watch out for that could signal a serious side effect of Carbimazole?

A: Official documents describe that symptoms such as fever, sore throat, mouth ulcers, increased bruising, or bleeding are signals that may warrant immediate attention from a healthcare provider. These signs are associated with serious blood disorders like agranulocytosis.

Q: Why is there a warning about fever or sore throat when taking Carbimazole?

A: These specific symptoms are noted in official safety information because they can suggest the development of a serious blood condition called agranulocytosis. Agranulocytosis is a severe and rare reduction in white blood cells that would leave the body highly vulnerable to infection.

Q: Is hair thinning or hair loss a permanent side effect of Carbimazole?

A: Hair loss or thinning has been reported occasionally as an adverse reaction to this medicine. Some patient resources indicate that the hair may regrow, although a timeline for this return is often uncertain. This is noted in the drug's safety profile.

Q: Can Carbimazole affect my sense of taste?

A: Official safety documents indicate that a loss of sense of taste has been observed and reported as an adverse reaction to Carbimazole. If a patient experiences a change in taste perception, it is noted as an effect associated with the medication.

Q: Does Carbimazole interact with over-the-counter pain relievers?

A: While caution is always advised when taking any medicine together, specific interactions with most over-the-counter pain relievers, such as paracetamol or ibuprofen, are not specifically detailed in the official drug-drug interaction sections. Official product information suggests providing a healthcare professional with a full list of all co-administered medicines.

Q: Are there any specific vitamins or supplements that should not be taken with Carbimazole?

A: Official drug documents warn that excess iodine intake (which can come from supplements) is documented to reduce the drug's effectiveness. Regulatory documents suggest informing a healthcare professional about all supplements being taken.

Q: Why are regular blood tests needed while taking Carbimazole?

A: Regular blood tests are essential for two key reasons, according to official information. First, they monitor thyroid hormone levels to check the drug is working effectively and that the thyroid function is being controlled. Second, these tests monitor blood cell counts to help detect serious side effects, particularly agranulocytosis.

Q: How often are blood tests typically required when first starting Carbimazole?

A: Clinical guidance indicates that blood tests are typically performed every six weeks or so when treatment is first started. This frequent testing is needed until hormone levels are stable. Once stability is achieved, the required frequency of testing may decrease.

Q: Can a patient stop taking Carbimazole suddenly if they feel better?

A: Official patient information indicates that stopping Carbimazole should not be done without first consulting a healthcare provider. Abrupt cessation of the medication can lead to a quick increase in thyroid hormone levels, potentially causing the hyperthyroidism to return or worsen.

Q: What happens if a patient misses one dose of Carbimazole?

A: If a dose is missed, patient information suggests the dose may be taken as soon as it is remembered. If it is nearly time for the next scheduled dose, specific instructions regarding how to proceed are usually detailed in the drug's patient information leaflet.

Q: Is Carbimazole known to affect fertility or affect men's sperm?

A: The underlying condition, hyperthyroidism, is associated with abnormalities in male sperm motility. Regulatory-cited research has indicated that these abnormalities have been reported to improve or normalize once the patient achieves a euthyroid state following treatment with anti-thyroid medication.

Q: Does Carbimazole affect how contraception (birth control pills) works?

A: While regulatory warnings strongly advise women of childbearing potential to use effective contraception due to the risk of congenital malformations, there is no official warning documenting that Carbimazole specifically reduces the effectiveness of oral contraceptive pills. The focus is on preventing pregnancy during treatment.

Q: If Carbimazole stops working, what are the next steps typically considered?

A: In cases where Carbimazole therapy proves ineffective or is not tolerated, clinical guidance often outlines alternative, definitive treatment options. These options may include radioactive iodine ablation (RAIA) or a surgical procedure known as a thyroidectomy.

Q: Can Carbimazole make me feel unusually tired or dizzy?

A: Official patient resources have listed both malaise (a general feeling of discomfort or tiredness) and dizziness as reported adverse effects. If a patient experiences these effects, they are noted as being potentially related to the medication.

Q: Can Carbimazole treatment cause hypothyroidism (underactive thyroid)?

A: Yes, official safety information notes that high doses of the drug can lead to a condition known as iatrogenic hypothyroidism, which is hypothyroidism caused by medical treatment. The 'blocking-replacement' regimen is a specific dosing strategy designed to help prevent this outcome.

Q: What should be done if a rash develops after starting Carbimazole?

A: Rash is listed as a common and usually self-limiting side effect. However, if the rash is severe or becomes generalized over the body, official information indicates that the drug's use should be discontinued immediately, as this can signal a serious systemic reaction.

Q: Does the time of day I take Carbimazole make a difference in its effectiveness?

A: When starting treatment, the initial dose is split into two or three daily doses that are generally advised to be spaced evenly. For the single daily maintenance dose, there is no specific instruction for an optimal time of day, such as morning versus evening, to enhance effectiveness.

Q: Is the low white blood cell count side effect always reversible if the drug is stopped?

A: The serious blood disorder (agranulocytosis) associated with the drug is generally considered reversible. Clinical studies analyzing this drug-induced disorder often require that the patient shows complete recovery after stopping the drug to classify the event as related to the medication.

Q: Do patients need to avoid being around sick people while taking Carbimazole?

A: Due to the rare risk of developing agranulocytosis, which severely impairs the body's ability to fight infection, official warnings state that if a patient feels generally unwell or suspects an infection, this information should be reported promptly to a healthcare provider. This measure is in place due to the risk of agranulocytosis.

Q: Is Carbimazole a medication used worldwide?

A: Yes, Carbimazole is an internationally used medication. Databases listing drug information show that it is sold under various brand names in numerous countries across multiple continents, indicating its broad global use for treating hyperthyroidism.

How should Carbimazole be stored and disposed of?

Carbimazole tablets must be stored at a temperature not exceeding 25 C (77 F) to maintain the product's stability and labeled potency. The official labeling explicitly states that the medicine must not be refrigerated or frozen.

Storage and Protection

The product must be kept in its original container or package as a requirement to protect the tablets from light and moisture. This medication must also be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Official regulatory guidelines forbid disposing of unused, expired, or unwanted Carbimazole via wastewater or routine household waste. Patients must follow local regulatory procedures for pharmaceutical waste, which often involves returning the medicine to a pharmacy for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Carbimazole found in:

A-Z Index: